Oivi is developing a handheld, point-of-care ophthalmic device to detect preventable, vision threatening eye-diseases with its first focus being Diabetic Retinopathy (DR). The solution is based on application of artificial intelligence to automated image capture and diagnostics. DR is a microvascular complication of diabetes caused by long term damage due to uncontrolled blood glucose levels. It is the leading cause of preventable blindness among adults. An estimated 500 million people globally are affected by diabetes and this number is projected to increase to 650 million by 2045. Within 10 years of onset, 75 percent of diabetics will have some degree of DR. However, there is a 95% reduction in vision loss due to DR if patients were to receive early screening, accurate diagnosis and timely treatment. Diabetic retinopathy is difficult to diagnose in its early stages as it is asymptomatic, and hence, screening is the only way to identify such patients to prevent them from going blind. In the developed world only 50% of patients with diabetes get screenings in a given year despite recommendations by the American Diabetes Association. In addition, the gold standard of diagnosing DR i.e. retinal fundus cameras, are expensive and often unavailable in remote or developing parts of the world. The Oivi camera addresses these current unmet needs with its automated image capture and diagnosis thereby enabling screening of a large group of DR patients. Oivi enables early diagnosis and enables inexpensive and early treatment options. Thus preventing vision loss among a huge patient pool. Oivi plans to first target emerging markets like India, where the population has limited or no access to such screening programs. The Oivi device will be offered at a fraction of the cost compared to existing retinal cameras thereby expanding the market to the vast majority of primary care facilities and diabetic clinics.
Project leader: Alex George
Institution: OIVI AS